Published in Biomed Res Int on December 23, 2013
Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients. Oncotarget (2015) 0.78
Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer. J Cancer Res Clin Oncol (2016) 0.75
Molecular features that predict the response to antimetabolite chemotherapies. Cancer Metab (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med (2004) 25.68
5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol (2005) 6.00
Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis (1997) 5.81
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol (2012) 5.41
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res (2000) 3.42
Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol (2004) 2.95
Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet (1989) 2.15
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.95
Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer (2007) 1.86
Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther (2008) 1.83
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. J Clin Oncol (1997) 1.76
Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol (2003) 1.67
Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg (2005) 1.64
Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol (2003) 1.40
Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res (2001) 1.23
Modern management of rectal cancer: a 2006 update. World J Gastroenterol (2006) 1.20
A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol (2008) 1.18
Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol (2006) 1.17
Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys (2002) 1.13
A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer (1991) 1.09
Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res (2003) 1.09
Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol (2004) 1.04
p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res (1997) 1.03
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol (2008) 1.02
Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis (2009) 0.98
The correlation between tumour regression grade and lymph node status after chemoradiation in rectal cancer. Colorectal Dis (2008) 0.96
GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer (2009) 0.92
Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncol Rep (2001) 0.91
Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett (2005) 0.91
Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Oncol Rep (2012) 0.91
Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today (2011) 0.89
Hypoxia-related proteins in patients with rectal cancer undergoing neoadjuvant combined modality therapy. Dis Colon Rectum (2012) 0.85
EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 as potential prognostic markers for postoperative Taiwanese colorectal cancer patients. DNA Cell Biol (2011) 0.85
Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Pract Res Clin Gastroenterol (2002) 0.83
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. J Surg Oncol (2010) 0.83
Preoperative radiotherapy downregulates the nuclear expression of hypoxia-inducible factor-1alpha in rectal cancer. Scand J Gastroenterol (2010) 0.82
Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2012) 0.79
Prognostic significance of tumor regression grade after preoperative chemoradiotherapy for rectal cancer. J Korean Soc Coloproctol (2011) 0.78
Laparoscopic assisted distal rectal cancer resection with preoperative concurrent chemoradiotherapy. Cancer Res Treat (2007) 0.77